Prelude Therapeutics Incorporated (PRLD) is a publicly traded Healthcare sector company. As of May 21, 2026, PRLD trades at $4.51 with a market cap of $345.66M and a P/E ratio of -4.37. PRLD moved +5.50% today. Year to date, PRLD is +84.43%; over the trailing twelve months it is +358.25%. Its 52-week range spans $0.61 to $5.54. Analyst consensus is strong buy with an average price target of $7.67. Rallies surfaces PRLD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Prelude Therapeutics Advances PRT12396 Trial and Secures Cash Runway to Q2 2028: Prelude Therapeutics initiated enrollment of its Phase 1 trial for PRT12396 in polycythemia vera and myelofibrosis, and plans an IND filing for oral KAT6A degrader PRT13722 by mid-2026 with Phase 1 start in ER+ breast cancer later that year. Cash runway extends into Q2 2028 after a $90M underwritten offering.
| Metric | Value |
|---|---|
| Price | $4.51 |
| Market Cap | $345.66M |
| P/E Ratio | -4.37 |
| EPS | $-1.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.54 |
| 52-Week Low | $0.61 |
| Volume | 27 |
| Avg Volume | 0 |
| Revenue (TTM) | $16.72M |
| Net Income | $-77.80M |
| Gross Margin | 0.00% |
3 analysts cover PRLD: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.67.